

# Index

## A

- AAN-EFNS guidelines, 127
- Aberrant drug behaviors, risk for, 85, 86
- A $\beta$  axons, 21
- Ablation
  - auriculotemporal nerve, 379
  - trigeminal nerve pain
    - V1 distribution, 344
    - V-2 distribution, 348
    - V-3 distribution, 355
- Abnormal central transmission, 429
- Abnormal cervical VEMP (cVEMP), 280
- Abortive agents, 432, 434
- Abortive therapy, 140, 261, 432
- Acupuncture, 154, 156, 200, 201, 203–207, 432
  - head and neck pain, 199
    - acupuncture analgesia, 204
    - Chinese diagnosis, 205
    - Chinese medicine, 200, 201
    - meridians, 201, 203–204
    - microsystem acupuncture, 206, 207
    - pain management, incorporating acupuncture into, 207
    - pain syndromes and treatment, 205, 206
    - placebo effect, 207
- Acupuncture analgesia (AA), 204
- Acute (or abortive) migraine treatments, 397–400
- Acute apical periodontitis, 97
- Acute symptomatic medical management, 282
- Adjunctive agents, 432
- Advanced neurosurgical interventions, 252–257
  - brainstem
    - DBS, 256
    - lesions, 255
    - motor cortex stimulation, 257
  - CNS pathways, 252
  - spine
    - high cervical spinal cord neuromodulation, 254
    - nucleus caudalis DREZ lesioning, 252, 253
    - nucleus caudalis tractotomy-nucleotomy, 253
    - stereotactic mesencephalotomy, 254
- A $\delta$  fibers, 21
- American Academy of Neurology and the European Federation of Neurological Societies (AAN-EFNS) guidelines, 126
- American Association of Orofacial Pain (AAOP), 32
- American Headache Society (AHS), 131
- American Pain Society, 75
- Amitriptyline, 194, 436
  - adverse effects, 139
  - mechanisms of action, 138
  - migraine prophylaxis as monotherapy, 138
  - PHN, 138, 139
- Analgesic therapy, 432
- Anesthesia dolorosa (AD)
  - central lateral thalamotomy, 384
  - creepy crawly feeling, 381
  - deep brain stimulation, 383
  - diagnostic evaluation, 382
  - differential diagnosis, 382
  - dorsal root entry zone, 383
  - facial numbness and persistent V1/V2 burning pain, 381

- Anesthesia dolorosa (AD) (*Cont.*)  
 intraoperative microelectrode, 383  
 lightning electric pain, 381  
 microvascular decompression, 381  
 nucleus caudalis DREZ lesioning, 384  
 PAG stimulation, 383  
 right supraorbital neurectomy, 381  
 stereotactic radiosurgery, 381  
 thalamic sensory region, 383  
 trigeminal blocks, 381, 383  
 trigeminal deafferentation pain, 382  
 trigeminal neuralgia, 382
- Anger assessment, 82
- Anginal pain, 98
- Angioedema, 129
- Angiotensin II receptor blockers (ARB), 143
- Angiotensin-converting enzyme inhibitors (ACE-I), 143
- Anterior cingulate cortex (ACC), 255
- Antibiotic therapy, 364
- Anticonvulsant medications, 284
- Antiepileptics  
 carbamazepine, 126  
 gabapentin, 126–128  
 phenytoin, 129  
 pregabalin, 128, 129  
 topiramate, 130, 131  
 valproate, 131, 132
- Antihistamine/antiserotonin agent, 436
- Anti-inflammatory medications  
 corticosteroids, 133–135  
 NSAIDs, 132, 133
- Anxiety, 16, 17, 73, 74, 78, 80, 129, 168, 188, 189, 193, 257, 276, 282
- Anxiety screening tools, 82
- Arachnoid membrane, 243
- Artificial neural network (ANN), 38
- Aspirin, 132, 144
- Atlantoaxial joint, 120
- Atlanto-occipital joint, 119
- Atypical facial pain (AFP), 43, 44
- Atypical odontalgia (AO), 27, 32, 137
- Atypical trigeminal neuralgia, 43, 217, 335–338  
 type 2  
 Burchiel's classification, 336  
 clinical history, 335  
 conservative management, 338  
 diagnostic evaluation, 337  
 differential diagnosis, 336–337  
 idiopathic trigeminal neuralgia, 336  
 management, 338  
 microvascular decompression, 338  
 neuromodulation approaches, 338  
 rhizolysis procedures, 338  
 treatment options, 337–338
- Audiometry, 275, 279–280
- Auriculotemporal (ATN) nerves, 6, 108, 115, 116, 118, 162, 163
- Auriculotemporal neuralgia, 14, 15
- Autogenic relaxation, 192
- Autoimmune mucosal diseases, 160
- Autonomic cephalgias, 140
- Autonomic nervous system activity, 85
- Autonomic nervous system testing, 85
- Autonomic Technologies™, 300
- Autophony, 280
- “Axis II” protocol, 78
- Axonal injury, 23
- B**
- Bacillus botulinus*, 173
- Baclofen, 135
- Balloon compression, 228, 229
- Bárány Society classification system, 273
- Barrow Neurological Institute pain score, 212
- Basilar artery migraines, 431
- Basilar migraine, *see* Migraine with brainstem aura
- Battery for Health Improvement-2nd edition (BHI-2), 84
- Beck Depression Inventory scores, 81, 136
- Behavioral sleep interventions, 191
- Benign paroxysmal positional vertigo (BPPV), 272, 277
- Benign paroxysmal vertigo of childhood (BPVC), 280–281
- Beta-blockers, 142, 436  
 evidence, 142  
 mechanism of action, 142  
 side effects, 142  
 therapies, 195
- Bilateral face and head pain  
 ablation, 379  
 auriculotemporal nerve, 377, 378  
 diagnostic workup, 376  
 differential diagnosis, 376  
 medical therapy, 378  
 nerve decompression, 378  
 nerve resection, 379  
 patient history, 375  
 psychological evaluation and therapy, 379  
 superficial temporal artery looping, 377, 378  
 temple, 377  
 zygomaticotemporal nerve, 378
- Biofeedback, 191

- Biopsychosocial model, 87
- Bony spur, 366
- Botulinum toxin (BoNT), 154, 155, 159, 174, 177–180, 182, 183
  - contraindications, 175
  - evidence, 141
  - mechanism of action, 141, 174, 175
  - prophylaxis, migraine headaches, 176–179
  - side effects, 141
  - TMD, 182, 183
  - trigeminal neuralgia
    - dosing and administration, 180
    - treatment mechanism of, 179, 180
  - type A, 405
  - type B, 174
- Bradycardia, 228
- Brain-derived growth factor (BDNF), 24
- Brainstem
  - DBS, 256
  - high cervical spinal cord neuromodulation, 254
  - lesions, 255
  - motor cortex stimulation, 257
  - nucleus caudalis DREZ lesioning, 252, 253
  - nucleus caudalis tractotomy-nucleotomy, 253
  - stereotactic mesencephalotomy, 254
- Brief version (BBHI-2), 84
- Bupivacaine, 113, 114, 167, 168
- Burchiel classification, 32
- Burning mouth syndrome (BMS), 16, 17, 100, 156
  - duloxetine, 137
  - gabapentin, 127
  - milnacipran, 138
- C**
- CAGE-AID assessment, 86
- Calcitonin gene-related peptide (CGRP), 177
- Calcium channel blockers, 142, 143, 436
- Canadian Headache Society, 195
- Cannabinoids
  - mechanism of action, 144, 145
  - pain states, 145
  - side effects, 145
- Capsaicin
  - cluster headaches, 141
  - evidence for migraines, 141
  - mechanism of action, 140
  - side effect, 141
- Carbamazepine, 239
  - adverse effects, 126
  - evidence for trigeminal neuralgia, 126
  - mechanism of action, 126
- Catastrophizing, 83, 188
- Celecoxib, 132
- Center for Epidemiological Studies—Depression Scale, 81
- Central catecholaminergic system, 429
- Central lateral (CL) thalamotomy, 384
- Central neuromodulation techniques, 317–323
  - cervical spinal cord stimulation
    - clinical use, 317
    - mechanism, 317
    - medication-resistant trigeminal autonomic cephalalgias, 318
    - operative technique, 317–318
  - deep brain stimulation
    - clinical evidence, 323
    - clinical use, 319
    - mechanism, 319
    - medication-resistant trigeminal autonomic cephalalgias, 320–321
    - operative technique, 322–323
- Central sensitization, 22, 24
- Centromedian/parafascicular (CM/Pf) thalamic complex, 383
- Cervical plexus dermatomal pain, 423
- Cervical plexus pain
  - ablation, 424
  - diagnostic workup, 423
  - differential diagnosis, 423
  - elongated styloid process, 424
  - gabapentin, 423
  - hydrocodone, 423
  - lesser occipital branch, 421
  - liposomal bupivacaine injection, 424
  - nerve decompression, 424
  - nerve resection, 424
  - patient history, 421
  - primary injection, 424
  - sternocleidomastoid muscle, 421
  - tramadol, 423
  - transverse cervical nerve, 422
  - upper cervical plexus sensory innervation, 421, 422
- Cervical spinal cord stimulation (SCS)
  - clinical use, 317
  - mechanism, 317
  - medication-resistant trigeminal autonomic cephalalgias, 318
  - operative technique, 317–318
- Cervicogenic headache, 119, 120
- C2–C3 facet (zygapophyseal) joint, 120
- C fibers, 21
- C2 ganglionectomy, 414

- Childhood headaches, *see* Pediatric migraines
- Chinese diagnosis, 205
- Chinese medicine, 200, 201
- Chronic apical periodontitis, 97
- Chronic daily headache (CDH) prophylaxis, 136
- Chronic migraines, 261
- Chronic orofacial pain, 33, 155
- Chronic pain, 22, 23, 69–72, 74, 78, 81, 82, 84
- Chronic tension-type headache, 136
- Chronification, 71
- Clostridium botulinum*, 174
- Cluster headache (CH), 141, 313
- Cogniphobia, 82
- Cognitive impairment, 84, 85
- Cognitive-behavioral therapy (CBT), 188, 437
  - activity pacing, 189, 190
  - assumption, 188
  - cognitive restructuring, 189
  - negative thought patterns, 188, 189
  - relaxation strategies/biofeedback, 190, 191
  - sleep hygiene, 190
- Collagen, 203
- Combined Cleveland Clinic and Mid-Michigan Medical Center series, 213, 214
- Conservative therapy, 413
- Contact point headaches, 366
- Contrast-enhanced head CT (CECT), 60
- Conversion disorder, 86
- Corrected QT (QTc), 139
- Cortical spreading depression, 429
- Corticosteroids
  - adverse effects, 134, 135
  - GCA, 133, 134
  - mechanism of action, 133
  - ophthalmoplegic migraine, 134
  - Tolosa-Hunt syndrome, 134
  - treatment of optic neuritis, 134
- CPAP therapy, 85
- Cranial neuralgias, 13, 426
- CT angiography (CTA), 60
- Current of injury, 203
- Current Opioid Misuse Measure, 86
- Cyclooxygenase enzymes (COX), 132
- Cylindrical electrodes, 291
- Cyproheptadine, 436
- D**
- Deep brain stimulation (DBS), 256
  - clinical evidence, 323
  - clinical use, 319
  - mechanism, 319
  - medication-resistant trigeminal autonomic cephalalgias, 320–321
  - operative technique, 322–323
- Dental origin
  - antibiotic therapy, 364
  - clinical history, 363
  - differential diagnosis, 362–363
  - foul-tasting postnasal drip, 361
  - irrigation and debridement, 364
  - left facial pain, 361
  - left maxillary posterior dentition, 364
  - left maxillary sinusitis, 364
  - maxillofacial CT, 363
  - nasal congestion, 361
  - orofacial pain, 362
  - physical examination, 363
  - referral, 363
  - tooth extraction, 364
- Depression, 16, 17, 73, 81, 116, 429, 436
- Depression screening tools, 81, 82
- Diagnostic and Statistical Manual criteria, 80
- Diagnostic Criteria for TMD (DC/TMD), 78
- Diagnostic nerve blocks, 104, 106–109
  - anesthetics, 110
  - applied anatomy
    - greater occipital nerve, 108, 109
    - trigeminal nerve, 104, 106–108
    - upper cervical plexus nerves, 109
  - auriculotemporal nerve block, 115, 116, 118
  - greater occipital nerve block, 116, 117
  - inferior alveolar nerve block, 113, 114
  - infraorbital nerve block, 112, 113
  - injection technique, 110, 111
  - lesser occipital and greater auricular nerve block, 117
  - mental nerve block, 114
  - posterior superior alveolar nerve block, 113
  - supraorbital and supratrochlear nerve blocks, 106, 112
  - trigeminal neuralgia, 103
  - zygomaticotemporal nerve block, 113, 118
- Diaphragmatic breathing, 192
- Dihydroergotamine, 144
- Divalproex, 194
- Dizziness, 273, 274
- Dorsal root entry zone (DREZ), 25, 383
- Dronabinol, 145
- Drug Abuse Screening Test (DAST), 86
- Duloxetine, 137, 196

**E**

Eagle's syndrome, 14  
 Ectatic basilar artery, 246  
 Ectopic activity, 24  
 Electrocochleography (ECoG), 279  
 Electrodes, 256  
 Elongated styloid process, 424  
 Endolymphatic hydrops, 280  
 Episodic migraine, 392  
 Episodic vertigo, 273, 274, 278  
 Epworth Sleepiness Scale, 85  
 Erb's point, 9  
 Ergot derivatives, 144  
 Ergotamines, 144, 434  
 Ethmoidal nerves, 263  
 EuroQol (EQ-3D), 257  
 Extra-articular disorder, 158

**F**

Face dermatomes, 3  
     greater occipital nerve, 9  
     trigeminal nerve, 4–6  
     upper cervical plexus, 7, 9  
 Facial pain, 31, 53, 120, 121  
     additional antineuropathic drugs, 388  
     Burchiel TN classification, 37  
     case history, 385  
     category of, 31  
     classical TN, ICHD-3 beta diagnostic  
         criteria, 39  
     classifications, 33  
     diagnostic questionnaires, 37, 38  
     diagnostic workup, 387  
     differential diagnosis, 45, 46, 386  
     global sympathectomy model, 386  
     history, 53, 54  
     IASP and IHS classification, 46  
     ICHD-3 beta classification, 34  
     interventional pain block, 386  
     interventional procedures for, 155  
     neurolysis, 388  
     pediatrics, 426  
     peripheral nerve stimulator implantation,  
         388  
     phenotypic patterns of, 251  
     primary afferent neurons, 385  
     stellate ganglion block, 387, 388  
     sympathetically mediated facial pain, 386  
     treatment of, 252  
     tricyclic antidepressants, 388  
 Food-borne botulism, 172  
 Foramen ovale cannulation

anatomic landmarks, 224  
 radiographic localization, 226  
 skull base anatomy for, 225

**Frontal migraine**

botulinum toxin type A, 405  
 case history, 403  
 diagnostic workup, 404–405  
 differential diagnosis, 404  
 endoscopic procedures, 405  
 general anesthesia, 405  
 local anesthetic injection, 405  
 medical management, 405  
 nerve resection, 405  
 peripheral neuralgia, 403  
 transpalpebral (upper blepharoplasty)  
     approach, 405, 406

**G****Gabapentin**

adverse effects, 128  
 burning mouth syndrome, 127  
 evidence for postherpetic neuralgia, 127  
 evidence for trigeminal neuralgia, 127  
 mechanism of action, 126  
 post-traumatic trigeminal neuropathy  
     (anesthesia dolorosa), 127  
 trigeminal trophic syndrome, 127

Gamma aminobutyric acid (GABA), 126, 131,  
 135, 136

Gamma knife radiosurgery, 64, 211–218, 240  
 trigeminal neuralgia

    combined Cleveland Clinic and  
     Mid-Michigan Medical Center  
     series, 213, 214

    dose prescription, 215

    isocenter placement, 214

    medical refractory trigeminal neuralgia,  
     211

    medically refractory atypical trigeminal  
     neuralgia, 217

    microvascular decompression and  
     rhizotomy, 218

    multiple sclerosis-related trigeminal  
     neuralgia, 216, 217

    Ruber International Hospital series, 213

    University of Arkansas series, 212, 213

    University of Pittsburgh series, 211,  
     215

    Wake Forest University series, 215, 216

GammaCore® percutaneous VNS system, 306

Generalized anxiety disorder-7 (GAD-7), 82

Geniculate neuralgia, 42

Giant cell arteritis (GCA), 133, 134  
 Global sympathectomy model, 386  
 Glossopharyngeal nerve, 67  
 Glossopharyngeal neuralgia, 14, 25, 42, 66, 67, 235  
 Glycerol injection, 227  
 Glycerol rhizotomy (GR), 222, 227, 229  
 G protein-coupled receptors, 22  
 Greater auricular nerve block, 9, 109, 117, 166  
 Greater occipital nerve, 9, 10, 108, 109, 116, 117, 164, 166  
 Greater occipital neuralgia (GON), 409, 410

## H

Head and facial pain, 187–196  
 acute to chronic pain, 22  
 central sensitization, 24  
 idiopathic, 27, 28  
 inflammatory conditions, 26  
 neuralgias, 24–26  
 neuropathic pain, 23, 24  
 nociceptive physiology, 21  
 non-pharmacological headache interventions  
 CBT, 188–191  
 family support, role of, 193  
 operant behavioral conditioning, 192  
 peripheral sensitization, 22, 23  
 pharmacological interventions  
 beta-blocker therapies, 195  
 MAOI therapies, 193, 194  
 SSRIs and SNRIs, 195, 196  
 tricyclic therapies, 194, 195  
 placebo effects, 196  
 Head and neck pain, 200, 201, 203–207, 417, 418  
 acupuncture, 199  
 analgesia, 204  
 Chinese diagnosis, 205  
 Chinese medicine, 200, 201  
 meridians, 201, 203, 204  
 microsystem acupuncture, 206, 207  
 pain management, incorporating acupuncture into, 207  
 pain syndromes and treatment, 205, 206  
 placebo effect, 207  
 alternative management options, 419  
 diagnostic workup, 418  
 differential diagnosis, 418  
 fentanyl patch, 419  
 liquid oxycodone, 419  
 Maalox, 419

radiation-induced mucositis  
 amplification, 418  
 definition, 417  
 generation of messenger signals, 418  
 healing, 418  
 initiation, 418  
 occurrence, 417  
 ulceration, 418  
 superior laryngeal nerve block, 419  
 T3N2c squamous cell carcinoma, 417  
 Head dermatomes, 3, 9  
 trigeminal nerve, 4–6  
 upper cervical plexus, 7, 9  
 Head motion vertigo, 274  
 Head motion-induced dizziness, 274  
 Head pain, 13–17, 55  
 etiology of  
 auriculotemporal neuralgia, 14, 15  
 burning mouth syndrome, 16, 17  
 glossopharyngeal neuralgia, 14  
 occipital neuralgia, 15  
 optic neuritis, 16  
 persistent idiopathic facial pain, 17  
 postherpetic neuralgia, 15, 16  
 superior laryngeal neuralgia, 16  
 trigeminal neuralgia, 13, 14  
 and facial pain (*see* Head and facial pain)  
 history, 55  
 imaging, indications for, 59, 60  
 modalities and techniques, 60  
 and neck pain (*see* Head and neck pain)  
 pediatric (*see* Pediatric migraines)  
 physical exam, 56, 57  
 Health psychology, 76  
 Headache disorders, 44  
 Hemifacial spasm, 235  
 Hemiplegic migraine, 392, 431  
 Herpes zoster, 205  
 High cervical spinal cord neuromodulation, 254  
 Hyperalgesic priming, 23  
 Hypochondriasis, 86

## I

Idiopathic facial pain, 27, 28  
 Idiopathic trigeminal neuralgia, 40, 336  
 Ignition hypothesis, 24  
 IMMPACT guidelines, 80  
 IncobotulinumtoxinA, 182  
 Inferior alveolar nerve, 113–115  
 Inflammation, 176  
 Inflammatory conditions, 26  
 Infraorbital nerve, 4, 104, 112, 113, 347, 348  
 Infratrochlear nerve, 4, 104

- Injectable steroids, 159
- Injection technique, 167
- Institute of Medicine (IOM) report, 71
- Internal vertigo, 273
- International Association for the Study of Pain (IASP), 32, 71, 75, 120
- International Classification of Diseases (ICD), 32
- International Classification of Headache Disorders (ICHD), 32, 33
- International Headache Classification, 120
- Interventional treatments, 401
- Intra-articular disorders, 158
- Intravenous methylprednisolone, 134
- Irreversible pulpitis, 97
- Isocenter placement, 214
- Isomethptene, 434
  
- K**
- Kenalog, 113
- Kerner, Justinus, 172
- Keyhole craniotomy, 243
- Kinesiophobia, 73, 82
  
- L**
- Left maxillary posterior dentition, 364
- Left maxillary sinusitis, 364
- Lesser occipital branch, 421
- Lesser occipital nerve, 9, 109, 117, 166
- Lesser occipital neuralgia (LON), 409, 410
- Lidocaine
  - autonomic cephalgias, 140
  - evidence for migraines, 140
  - mechanism of action, 139, 140
  - side effects, 140
  - trigeminal neuralgia, 140
- Life-span approach, 71
- Lingual nerve, 6, 108
- Lipopolysaccharides, 27
- Local anesthetic injection, 405
  
- M**
- Malignancy, 26
- Mandibular branch, 6
- Maxillary branch, 4
- Maxillary left second molar test, 364
- Maxillary nerve, 113
- Maxillary sinusitis, 98, 157, 158
- Maximal intensity projection (MIP)
  - reconstruction, 63, 66
- McGill Pain Questionnaire (MPQ), 79
- Meckel's cave, 223, 251
  
- Medical management
  - antiepileptics
    - carbamazepine, 126
    - gabapentin, 126–128
    - phenytoin, 129
    - pregabalin, 128, 129
    - topiramate, 130, 131
    - valproate, 131, 132
  - anti-inflammatory medications
    - corticosteroids, 133–135
    - NSAIDs, 132, 133
  - capsaicin, 140, 141
  - lidocaine, 139, 140
  - migraine abortives
    - cannabinoids, 144, 145
    - ergot derivatives, 144
    - triptans, 143, 144
  - migraine prophylactics
    - ACE Inhibitors/ARB Blockers, 143
    - beta-blockers, 142
    - botulinum toxin, 141, 142
    - calcium channel blockers, 142, 143
  - muscle relaxants
    - baclofen, 135
    - Tizanidine, 135, 136
  - non-opiate analgesics, 125
  - SNRI
    - duloxetine, 137
    - milnacipran, 137, 138
    - venlafaxine, 136, 137
  - TCAs (*see* Tricyclic antidepressants)
- Medical refractory trigeminal neuralgia, 211
- Medical therapy
  - auriculotemporal nerve, 378
  - trigeminal nerve pain, V-3 distribution, 355
- Medically refractory atypical trigeminal neuralgia, 217
- Ménière's disease (MD), 272, 277, 278, 280
- Meningitis, 240
- Mental nerve block, 114
- Meridians, 201–204
- Microsystem acupuncture, 206, 207
- Microvascular decompression (MVD), 64, 212, 218, 221, 238, 239, 241–244, 246, 247, 333, 338, 381
  - durability and complication profile of, 230
  - TN, 240
    - historical perspective, 238, 239
    - intradural dissection, 243, 244
    - long-term follow-up, 247
    - patient position and preparation, 241, 242
    - patient selection, 241
    - reconstruction and closure, 246
    - surgical technique, 241
    - treatment options, 239

- Migraine abortifacients, 276
- Migraine abortives  
  cannabinoids, 144, 145  
  ergot derivatives, 144  
  triptans, 143, 144
- Migraine headaches, 107, 108, 112, 161, 168, 177–179  
  botulinum toxin prophylaxis, 176–179  
  extracranial etiology, 175
- Migraine prophylactics  
  ACE inhibitors/ARB Blockers, 143  
  beta-blockers, 142  
  botulinum toxin, 141, 142  
  calcium channel blockers, 142, 143
- Migraine prophylaxis  
  amitriptyline, 138  
  nortriptyline, with combination therapy, 139  
  topiramate, 130  
  valproate, 131  
  venlafaxine, 136, 137
- Migraine with brainstem aura (MBA), 271, 392
- Migraines, 44, 55, 73, 263, 265–269, 278, 393, 395–401  
  anatomy  
    compression points, 263  
    frontal trigger area, 263  
    septum, 263  
    temporal trigger area, 263  
  basilar artery, 431  
  case management, 394–395  
  chronic migraine, 392  
  classification systems, 261  
  diagnosis, 264, 272  
  differential diagnosis, 393–394  
  episodic migraine, 392  
  etiology, 262  
  hemiplegic, 392, 431  
  history, 262  
  imaging, 394  
  incidence, 392  
  initial evaluation, 263  
  laboratory testing, 394  
  lifestyle modifications, 395  
  lifetime prevalence, 273  
  local anesthetic nerve injection, 264  
  medical therapy, 262  
  motion sickness, 391  
  nonpharmacological treatments, 262  
  onabotulinumtoxinA, 261  
  pharmacologic treatments, 261  
    acute/abortive treatments, 397–400  
    interventional treatments, 401  
    preventive treatments, 395–397  
    rescue treatments, 393, 400  
  physical examination, 264  
  prevalence, 261  
  socioeconomic burden, 261  
  surgical management  
    auriculotemporal nerve, 269  
    bony foramen, 265, 266  
    lesser occipital nerve, 269  
    occipital nerve release, 267, 269  
    open transpalpebral incision/  
      endoscopic approach, 265  
    risks, 269  
    supratrochlear and supraorbital nerves, 266  
    zygomaticotemporal nerve, 265, 267, 268  
  trigger avoidance, 395  
  vascular events, 392  
  with/without aura, 272, 392
- Millon Behavioral Medicine Diagnostic (MBMD), 84
- Milnacipran, 137, 138
- Mini Mental Status Exam (MMSE), 85
- Minnesota Multiphasic Personality Inventory (MMPI-2), 84, 87
- MMPI profile, 84
- Modified Somatic Perception Questionnaire (MSPQ), 87
- Monoamine oxidase inhibitor (MAOI), 193, 194
- Monotherapy, 195
- Mood symptoms, 80, 81
- Motion sickness, 277
- Motor cortex stimulation (MCS), 257
- Mucosal diseases, 100, 160
- Multiple Ability Self-Report Questionnaire (MASQ), 85
- Multiple sclerosis, 14, 25
- Multiple sclerosis-related trigeminal neuralgia, 216, 217
- Multiple scoring systems, 418
- Muscle relaxants  
  baclofen, 135  
  tizanidine, 135, 136
- Myofascial TMD pain, 99, 159
- N**
- Nabilone, 145
- Nadolol, 436
- Naproxen, 132
- Narrow steerable paddle electrodes, 291
- Nasal origin  
  anticonvulsants, 368

- bony spur, 366
  - clinical history, 368
  - CT scan, 368
  - decongestant and topical anesthetics, 368
  - differential diagnosis, 367
  - nasal turbinates, 368
  - pain medications, 368
  - patient history, 365
  - physical examination, 368
  - pterygopalatine ganglion, 366, 367
  - sphenopalatine ganglion blocks, 368
  - Nasal septoplasty, 368
  - Nasal turbinates, 368
  - Neck dermatomes, 3
  - Negative thought pattern, 188, 189
  - Nerve decompression, 355, 378
  - Nerve resection, 405
  - Nervus intermedius neuralgia, 43
  - Neuralgia, 24–26, 39–43
    - differential diagnosis, 38, 39
    - geniculate neuralgia, 42
    - glossopharyngeal neuralgia, 42
    - nervus intermedius neuralgia, 43
    - occipital neuralgia, 43
    - paratrigeminal neuralgia, 42
    - sluder neuralgia, 42
    - superior laryngeal neuralgia, 42
    - trigeminal neuralgia/trigeminal pain, 39–41
    - trigeminal (*see* Trigeminal neuralgia)
  - Neurocognitive testing, 84, 85
  - Neuromas, 26
  - Neuromodulation approaches, 338
  - Neuropathic pain, 23, 24, 31, 100, 159, 237
  - Neurotoxin, 174
  - Ninth cranial nerve (CNIX), 66
  - Non-enhanced computed tomography (NECT), 60
  - Noninvasive VNS (nVNS), 305–307
  - Non-odontogenic oral-dental pain, 98
    - maxillary sinusitis, 157–158
    - mucosal diseases, 160
    - myofascial TMD pain, 159
    - neuropathic pain, 159
    - temporomandibular disorders, 158
  - Non-opiate analgesics, 125
  - Nonorganic syndromes, 86
  - Non-pharmacologic modalities, 432
  - Nonselective beta-blockers, 436
  - Nonsteroidal anti-inflammatory drugs (NSAIDs), 155
    - adverse effects, 133
    - mechanism of action, 132
    - TMJ in Adults, 132, 133
  - Norepinephrine, 138
  - Nortriptyline, 139
  - Nuchal line, 9
  - Nucleus caudalis DREZ lesioning, 252, 253
  - Nucleus caudalis tractotomy-nucleotomy, 253
  - Numerical rating scale (NRS), 79
  - Nystagmus, 274
- O**
- Occipital nerve stimulation (ONS), 291, 293, 295–297, 410
    - clinical evidence, 316–317
    - clinical results
      - cluster headache, 297
      - medically refractory chronic migraine, 295–297
      - occipital neuralgia, 295
    - clinical use, 315
    - indications, 290
    - mechanism, 316
    - permanent system, 294–295
    - trial electrode implantation
      - operative pearls, 293
      - patient positioning, 291
      - postoperative care, 293
      - preoperative considerations, 291
      - standard surgical preparation and draping, 291
      - surgical steps, 291
  - Occipital neuralgia (ON), 15, 43, 295
    - blood work, 411
    - case history, 409
    - C2 ganglionectomy, 414
    - clinical history, 410, 411
    - conservative therapy, 413
    - differential diagnosis, 411
    - GON, 409, 410
    - local anesthetic blocks, 410, 411
    - LON/third occipital nerves, 409, 410
    - medications, 410
    - occipital nerve stimulation, 410
    - occipital neurectomy, 413
    - physical examination, 410, 411
    - postoperative x-rays, 413
    - refractory, 410
    - rhizotomy, 414
    - steroid injections, 410
    - trial occipital nerve stimulator electrode implantation, 412
  - Occipital neurectomy, 413
  - Occlusal splint therapy, 359
  - Ocular VEMP (oVEMP), 280
  - Oculinum, 174

- Odontogenic dental pain, 95, 96  
 Odontogenic pain, 95, 156, 362  
 Oligodendrocytes, 237  
 OnabotulinumtoxinA, 261  
 Oncologic disease, 160  
 Ophthalmic branch, 4  
 Ophthalmic nerve, 104  
 Ophthalmoplegic migraine, 134  
 Opioid risk assessment, 86  
 Opioid risk tool, 86  
 Opioids, 432  
 OPPERA study, 81  
 Optic neuritis, 16, 134  
 Oral methylprednisolone, 134  
 Oral mucosa, 100  
 Oral prednisone, 134  
 Oral preventive treatments, 395–397  
 Oral-dental pain, 154–156
  - evidence-based management of, 153, 154
    - acupuncture, 154
    - botulinum toxin, 154, 155
    - burning mouth syndrome, 156
    - facial pain, interventional procedures for, 155
    - medication treatment efficacy and chronic orofacial pain, 155
  - odontogenic pain, 157
  - periodontal pain, 157
  - tooth-related pain, 156
- Orofacial pain, 32
  - burning mouth syndrome, 100
  - maxillary sinusitis, 98
  - mucosal diseases, 100
  - myofascial TMD pain, 99
  - neuropathic pain, 100
  - non-odontogenic dental pain, 98
  - odontogenic dental pain, 95, 96
  - oral hard tissues, 95
  - oral soft tissue, 95
  - periodontitis, 97
  - pulpitis, 97
  - temporomandibular pain, 98, 99
  - tooth anatomy, 96
- Oswestry Disability Index, 80  
 Otoacoustic emission testing, 279  
 Oxcarbazepine, 239
- P**
- Pain Anxiety Symptoms Scale (PASS-20), 82  
 Pain beliefs and attitudes, 82, 83  
 Pain Disability Index (PDI), 80, 87  
 Pain intensity, 78–80, 82, 87  
 Pain matrix, 252
- Pain syndromes, 205, 206  
 Pain-sensitive nerve fibers, 426  
 Paratrigeminal neuralgia, 42  
 Patient Global Impression of Change (PGIC), 127  
 Patient Health Questionnaire, 81  
 Pediatric migraines, 432–436
  - average hours of sleep, 437
  - case history, 425
  - classifications, 426
  - cognitive behavior therapy, 437
  - diet, 436
  - family therapy, 437
  - lack of physical activity and childhood obesity, 437
  - nonpharmacologic treatment, 437
  - pain-sensitive nerve fibers, 426
  - pathophysiology, 428–429
  - prevalence, 426
  - primary headaches, 427
  - prophylactic therapy, 434
  - relaxation techniques, 437
  - secondary headaches, 427, 428
  - sex differentiation, 426
  - stratified care approach, 432
  - stress, 437
  - symptoms, 432
  - temporal patterns, 426, 427
  - treatment agents
    - abortive agents, 432–434
    - adjunctive agents, 432
    - analgesic therapy, 432
    - antihistamine/antiserotonin agent, 436
    - calcium channel blockers, 436
    - common medications, 432, 433
    - non-pharmacologic modalities, 432
    - nonselective beta-blockers, 436
    - prophylactic therapy, 435, 436
  - treatment goals, 431
    - with aura, 430, 431
    - without aura, 429, 430
- Percutaneous balloon compression (PBC), 222, 381  
 Percutaneous lesioning techniques, 222  
 Periaqueductal gray (PAG), 383  
 Pericranial peripheral nerve blocks, 401  
 Periodontal disorders, 96  
 Periodontal ligament, 95  
 Periodontal pain, 157  
 Periodontitis, 97  
 Peripheral cutaneous nerves, 178  
 Peripheral injury, 23  
 Peripheral nerve compression, 263  
 Peripheral nerve field stimulation (PNFS), 290

- Peripheral nerve stimulation (PNS), 290–295, 297–307
- occipital nerve stimulation
    - cluster headache, 297
    - indications, 290
    - medically refractory chronic migraine, 295
    - occipital neuralgia, 295
    - permanent system, 294
    - trial electrode implantation, 291–293
  - sphenopalatine ganglion
    - application, 300
    - clinical results, 304–305
    - cranial autonomic symptoms, 300
    - microstimulator device, 300–302
    - postoperative care, 304
    - PPF, 301
    - pterygomaxillary fissure, 301
    - surgical steps, 301
    - thin cut facial bone CT, 301, 303
  - supraorbital nerve stimulation
    - clinical results, 299–301
    - surgical steps, 298–299
- Peripheral nerves, 21
- Peripheral neuralgia, 403
- Peripheral neuromodulation techniques, 314–317
- occipital nerve stimulation
    - clinical evidence, 316–317
    - clinical use, 315
    - mechanism, 316
  - SPG stimulation and lesioning
    - clinical evidence, 314–315
    - mechanism and clinical use, 314
- Peripheral sensitization, 22, 23
- Peripheral trigeminal neuritis, 104
- Peripheral trigger point theory, 262
- Persistent idiopathic facial pain (PIFP), 17, 27, 44, 130
- Petrosal vein complex, 243
- Phantom face pain, *see* Anesthesia dolorosa
- Pharmacologic prophylaxis, 282–284
- Phenytoin
  - adverse effects, 129
  - in facial pain, 129
  - mechanism of action, 129
- Phonophobia, 275
- Photophobia, incapacitating, and nausea (PIN), 394
- PHQ-2, 82
- PHQ-9, 82
- Pittsburgh Sleep Quality Index, 85
- Placebo effect, 196, 207
- Positional vertigo, 274
- Positive fistula test, 280
- Post herpes zoster neuritis
  - alcohol injection, 374
  - diagnostic evaluation, 372
  - differential diagnosis, 372
  - medications, 372
  - nerve blocks, 371, 372, 374
  - nerve stimulator electrode, 374
  - nerve stimulator implant, 372, 373
  - patient history, 371
- Posterior fossa, 14
- Posterior inferior cerebellar artery (PICA), 66
- Posterior superior alveolar nerve, 5, 106, 113, 163, 165, 346, 348
- Postherpetic neuralgia (PHN), 15, 16, 26, 40, 138, 139, 387
  - gabapentin, 127
  - pregabalin, 128
- Post-traumatic trigeminal neuropathy, 41, 127–129
- Preauricular pain, 98
- PREEMPT protocol, 401
- Pregabalin
  - adverse effects, 129
  - facial pain, 128
  - mechanism of action, 128
  - postherpetic neuralgia, 128
- Primary headache disorders, 392, 393, 426, 427, 431, 437
- Progressive muscle relaxation, 192
- Pro-inflammatory mediators, 428
- Prophylactic therapy, 434–436
- Psychological assessment, 70–71, 74
  - acute pain, 69
  - American Pain Society, 75
  - anger assessment, 82
  - anxiety screening tools, 82
  - autonomic nervous system activity, 85
  - chronic pain, 69–71, 74
  - components, 76
  - comprehensive pain inventories, 84
  - depression screening tools, 81, 82
  - International Association for the Study of Pain, 71, 75
  - interview and behavioral observations, 76
  - IOM report, 71
  - mood symptoms, 80, 81
  - neurocognitive testing, 84, 85
  - nonphysiological factors, 73
  - pain beliefs and attitudes, 82, 83
  - pain intensity and descriptive measures, 78–80
  - psychological evaluation, 73, 74
  - psychological testing, 78

- Psychological assessment (*Cont.*)  
 QoL/functional impact of pain, 80, 81  
 response bias, 86, 87  
 risk for aberrant drug behaviors, 85, 86  
 risk stratification models, 70  
 screening assessment, 75  
 sleep quality, 85  
 TMD, 73
- Pterygomaxillary fissure (PMF), 301  
 Pterygopalatine fossa (PPF), 300, 301  
 Pterygopalatine ganglion, 366, 367  
 Pulpal pain, 97  
 Pulpitis, 97, 157  
 Pulsante microstimulator system, 300, 304
- Q**
- Quality of Life (QoL)/functional impact of pain, 80, 81  
 Quality Standards Subcommittee of the American Academy of Neurology (AAN), 131
- R**
- Radiation-induced mucositis  
 amplification, 418  
 with burning sensation and pain, 418  
 definition, 417  
 generation of messenger signals, 418  
 healing, 418  
 initiation, 418  
 occurrence, 417  
 ulceration, 418
- Radiofrequency rhizolysis (RR), 222, 240  
 Radiofrequency rhizotomy, 226–228  
 Radiopaque iohexol, 228  
 Radiosurgery, 230  
 Rebound headaches, 397  
 Red flags, 427, 428  
 Reflex-evoked audiometry, 279  
 Refractory head and neck pain, 387  
 Refractory occipital neuralgia, 410  
 Relaxation techniques, 192, 437  
 Repeat radiosurgery, 211  
 Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 85  
 Rescue treatments, 393, 400  
 Retraining programs, 282  
 Reversible pulpitis, 97  
 Rhizolysis procedures, 338  
 Rhizotomy, 218, 414  
 Robust petrosal vein complex, 244
- Rotational vertigo, 277  
 Ruber International Hospital series, 213
- S**
- Sativex, 145  
 Schwann cells, 26  
 Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R), 86  
 Secondary headaches, 393  
 pediatrics, 426  
 red flags, 427, 428  
 Secondary trigeminal neuralgia, 41  
 Second-order neurons, 252  
 Selective serotonin reuptake inhibitors (SSRI), 195  
 Serotonin, 138  
 Serotonin-norepinephrine reuptake inhibitors (SNRI)  
 duloxetine, 137  
 milnacipran, 137, 138  
 venlafaxine, 136, 137  
 Short-lasting unilateral neuralgiform headache attacks (SUNHA), 313  
 Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), 313  
 Short-lasting unilateral neuralgiform headache attacks with cranial autonomic features (SUNA), 313  
 Sleep dysregulation, 190  
 Sleep hygiene, 190  
 Sleep quality, 85  
 Sluder's neuralgia, 42, 366  
 Somatoform disorders, 86  
 Sphenopalatine ganglion (SPG), 156, 314–315, 319  
 application, 300  
 clinical results, 304–305  
 cranial autonomic symptoms, 300  
 microstimulator device, 300–302  
 postoperative care, 304  
 PPF, 301  
 pterygomaxillary fissure, 301  
 stimulation and lesioning  
 clinical evidence, 314–315  
 mechanism and clinical use, 319  
 surgical steps, 301  
 thin cut facial bone CT, 301, 303
- Spine  
 high cervical spinal cord neuromodulation, 254  
 nucleus caudalis DREZ lesioning, 252, 253

- nucleus caudalis tractotomy-nucleotomy, 253
  - stereotactic mesencephalotomy, 254
  - Spontaneous intracranial hypotension (SIH), 120
  - Spontaneous vertigo, 273
  - Standard septoplasty techniques, 268
  - State-Trait Anger Expression Inventory (STAXI), 82
  - Steady-state free procession (SSFP), 62
  - Stellate ganglion block, 387, 388
  - Stereotactic mesencephalotomy, 254
  - Sternocleidomastoid (SCM) muscle, 8, 117, 421
  - Steroids, 134
  - Stevens-Johnson syndrome, 126
  - Subcutaneous neurostimulation, *see* Peripheral nerve field stimulation
  - Substance abuse assessment, 86
  - Sumatriptan, 143
  - Superior laryngeal neuralgia, 16, 42
  - Supraorbital nerve, 4, 7, 104, 106, 112
  - Supraorbital nerve stimulation (SONS)
    - clinical results, 299–301
    - surgical steps, 298–299
  - Supratrochlear nerve, 4, 7, 104, 106, 112
  - Symptomatic trigeminal neuralgia, 41
- T**
- Tao, 201
  - Temporal headache, 115, 206
  - Temporomandibular disorder (TMD), 27, 73, 79, 84, 85, 155, 158, 182, 183
    - botulinum toxin, 182, 183
    - management of, 181
  - Temporomandibular joint disease (TMJ), 99, 116, 132, 133
  - Temporomandibular pain, 98, 99
    - arthrocentesis, 359
    - arthroscopy, 359
    - arthrotomy, 359
    - clinical manifestation, 358
    - diagnostic work-up, 358–359
    - differential diagnosis, 358
    - internal derangement, 358, 359
    - occlusal splint therapy, 359
    - occlusion, 359
    - palpation, 359
    - panorex radiograph, 359
    - patient history, 357
  - Tension headaches, 9
  - Tetracaine, 114
  - Tetrahydrocannabinol (THC), 145
  - Therapeutic nerve blocks
    - greater occipital nerve, 164
    - procedure technique, 167, 168
    - trigeminal nerve, 162, 163
    - upper cervical plexus nerves, 166
  - Tic douloureux, 235
  - Tinel's sign, 382, 411
  - Tizanidine
    - adverse effects, 136
    - chronic daily headache prophylaxis, 136
    - chronic tension-type headache, 136
    - mechanism of action, 135
  - T3N2c squamous cell carcinoma, 417
  - Tolosa-Hunt Syndrome, 134
  - Tooth anatomy, 96
  - Tooth-related (odontogenic) pain, 156, 157
  - Topiramate
    - adverse effects, 130, 131
    - mechanism of action, 130
    - migraine prophylaxis, 130
    - persistent idiopathic facial pain, 130
    - trigeminal neuralgia, 130
  - Transient oculomotor nerve palsy, 229
  - Transient receptor potential vanilloid subfamily member 1 (TRPV1), 180
  - Transverse cervical branch, 166
  - Transverse cervical nerve, 9, 422
  - Traumatic injuries, 26
  - Tricyclic antidepressants (TCAs), 436
    - amitriptyline, 138, 139
    - nortriptyline, 139
  - Tricyclic therapies, 194, 195
  - Trigeminal autonomic cephalalgias (TAC), 44, 314
    - central neuromodulation (*see* Central neuromodulation techniques)
    - hemicrania, 313
    - paroxysmal hemicrania, 313
    - peripheral neuromodulation (*see* Peripheral neuromodulation techniques)
    - SUNHA, 313
  - Trigeminal cervical complex, 110
  - Trigeminal deafferentation pain, 40, 382
  - Trigeminal nerve, 4–6, 54, 55, 61, 109, 164
    - auriculotemporal nerve, 108
    - divisions, 104, 105, 108
    - inferior alveolar nerve, 108
    - infraorbital nerve, 104
    - infratrochlear nerve, 104
    - lingual nerve, 108
    - mandibular branch, 108
    - maxillary branch, 104
    - ophthalmic nerve, 104
    - peripheral trigeminal neuritis, 104

- Trigeminal nerve (*Cont.*)
- posterior superior alveolar nerve, 106
  - superior cerebellar artery compression of, 245
  - supraorbital nerve, 104
  - supratrochlear nerve, 104
  - therapeutic nerve blocks, 162, 163
  - ZTN, 106, 107
- Trigeminal nerve ganglion, 6
- Trigeminal nerve pain, 351–355
- V1 distribution
    - ablation, 344
    - clinical history, 342
    - decompression procedure, 343
    - differential diagnosis, 342
    - medical treatment, 343
    - medications, 342
    - patient history, 341
    - physical examination, 342
    - supraorbital and supratrochlear nerves, 343
    - trigemino-cervical complex, 341
  - V2 distribution
    - ablation, 348
    - clinical history, 347
    - differential diagnosis, 347
    - infraorbital nerve, 347, 348
    - maxilla, 346, 348
    - medical treatment, 348
    - medications, 348
    - nerve blocks, 347, 348
    - nerve resection, 348
    - pain recurrence, 348
    - patient history, 345
    - physical examination, 347
    - posterior superior alveolar nerve, 346, 348
    - zygomaticotemporal nerve, 346
  - V3 distribution, 354
    - ablation, 355
    - auriculotemporal nerve, 352
    - differential diagnosis, 353
    - Gamma Knife, 355
    - history, 353
    - imaging, 353
    - inferior alveolar and mental nerves, 352–354
    - lingual nerve, 352
    - lower mandibular teeth, 352
    - medical therapy, 355
    - medication, 353
    - motor function, 352
    - multiple sclerosis, 351
    - nerve block, 353, 355
    - nerve decompression procedures, 355
    - palpation, 353
    - physical examination, 353
    - sensory innervation, 352
- Trigeminal nerves, 5, 62, 108
- Trigeminal neuralgia (TN), 13, 14, 25, 35–36, 61, 103, 155, 179, 180, 211–218, 221–230, 235, 382
- baclofen, 135
  - botulinum toxin
    - dosing and administration, 180
    - treatment mechanism of, 179, 180
  - carbamazepine, 126
  - causes of, 25
  - clinical presentation and epidemiology, 236
  - gabapentin, 127
  - gamma knife radiosurgery
    - combined Cleveland Clinic and Mid-Michigan Medical Center series, 213, 214
    - dose prescription, 215
    - isocenter placement, 214
    - medical refractory trigeminal neuralgia, 211
    - medically refractory atypical trigeminal neuralgia, 217
    - microvascular decompression and rhizotomy, 218
    - multiple sclerosis-related trigeminal neuralgia, 216, 217
    - Ruber International Hospital series, 213
    - University of Arkansas series, 212, 213
    - University of Pittsburgh series, 211, 215
    - Wake Forest University series, 215, 216
  - idiopathic
    - type I, 39–40
    - type II, 25, 40
  - lidocaine, 140
  - modalities and techniques, 62, 63, 65
  - MVD, 240
    - historical perspective, 238, 239
    - intradural dissection, 243, 244
    - long-term follow-up, 247
    - patient position and preparation, 241, 242
    - patient selection, 241
    - reconstruction and closure, 246
    - surgical technique, 241
    - treatment options, 239

- pathophysiology, 179, 237
- percutaneous procedures for, 221
  - alternatives, 230
  - anatomic considerations, 223, 224
  - balloon compression, 228, 229
  - glycerol rhizotomy, 227, 229
  - modern use of, 222
  - operative management, 221
  - operative principles, 225, 226
  - patient selection, 222, 223
  - radiofrequency rhizotomy, 226–228
- postherpetic neuralgia, 40
- post-traumatic trigeminal neuropathy, 41
- prevalence of, 31
- secondary trigeminal neuralgia, 41
- topiramate, 130
- trigeminal deafferentation pain, 40
- Trigeminal neuralgia type 1 (TN1), 25
- Trigeminal neuralgia type 2 (TN2), 25
- Trigeminal neuritis
  - peripheral, 162
  - type I, 54, 104
    - diagnostic nerve blocks, 332
    - diagnostic tests, 333
    - differential diagnosis, 333
    - medications, 332
    - microvascular decompression, 333
    - severe, electric-like pain, 331, 332
- Trigeminal trophic syndrome, 127
- Trigemino-cervical complex (TCC), 108–109, 252, 341
- Trigeminovascular system, 428, 429
- Trigger point injections, 401
- Trigger points, 155, 159
- Triptans, 143, 144, 434
- Typical trigeminal neuritis, 104
  
- U**
- University of Arkansas, 212, 213
- University of Pittsburgh, 211, 215
- Upper cervical plexus nerves, 8, 109, 111, 166
  
- V**
- Vagal nerve stimulation (VNS), 305
- Valproate
  - adverse effects, 132
  - in facial pain, 131, 132
  - mechanism of action, 131
  - migraine prophylaxis, 131
- Varicella zoster viral (VZV) infection, 26
- Vascular compression, 61
- Vascular contact, 242
- Vasodilator medications, 276
- Venlafaxine
  - adverse effects, 137
  - mechanism of action, 136
  - migraine prophylaxis as monotherapy, 136, 137
- Venous compression, 244
- Verapamil, 436
- Vertigo, 277–279
  - clinical evaluation
    - audiometry, 279
    - CT imaging, 278
    - ECoG, 279
    - fluctuating sensorineural hearing loss, 279
    - MRI modality, 278
    - patient history, 277–278
    - physical examination, 278
    - ultrasonographic evaluation, 278
    - VEMP testing, 279
    - videonystagmography, 279
  - definition, 273
  - internal, 273
  - lifetime prevalence, 273, 274
- Vestibular migraine (VM), 273–279, 281–284
  - BPVC, 280
  - clinical features
    - ear-related symptoms, 275
    - hearing loss, 275–276
    - psychiatric comorbidity, 276
    - subjective tinnitus, 276
  - diagnostic criteria, 272, 276–277
  - dizziness, 273
  - follow-up and prognosis, 285
  - incidence, 271
  - management
    - acute, symptomatic management, 282
    - anticonvulsant medications, 281
    - classic migraine, 281
    - pharmacologic prophylaxis, 282–284
- MBA, 271
- Ménière's disease, 272, 277, 280
- nystagmus, 274
- otologists, 285
- triggers, 275
- vertigo
  - audiometry, 279
  - CT imaging, 278
  - definition, 273
  - ECoG, 279

- Vestibular migraine (VM) (*Cont.*)  
  episodic, 273, 274  
  internal, 273  
  lifetime prevalence, 273  
  MRI modality, 278  
  otoacoustic emission testing, 279  
  patient history, 277–278  
  physical examination, 278  
  ultrasonographic evaluation, 278  
  VEMP testing, 279  
  vestibular symptoms, 273, 275, 276
- Vestibular rehabilitation, 282
- Vestibular symptoms, 273, 275, 276
- Vestibular-evoked myogenic potential (VEMP)  
  testing, 279
- Videonystagmography (VNG), 279
- Visual analogue scales (VAS), 79
- Visually induced vertigo, 274
- W**
- Wake Forest University series, 215, 216
- Wallerian degeneration, 23, 26
- Western medicine, 200
- X**
- Xerostomia, 100
- Xylocaine, 110–114, 116, 117, 167, 168
- Z**
- Zygomaticotemporal (ZTN) nerves, 5, 106,  
  107, 114, 162, 163, 346  
  complete transection, 267, 268  
  direct approach, 267, 268  
  nerve block, 113, 118  
  transpalpebral incision, 265, 267